Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: Results of a prospective multicenter study

European Urology

Volumn 47, Issue 3, 2005, Pages 302-307

  Sözen, Sinan ^a   Eskicorapci, Saadettin ^b   Küpeli, Bora ^a   Irkilata, Lokman ^a   Altinel, Mert ^c   Özer, Gökhan ^c   Uygur, Cemil ^d   Alkibay, Turgut ^a   Özen, Haluk ^b  

^a GAZI UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

^d Ankara Onkoloji   (Turkey)

Author keywords

Complexed prostate specific antigen; Derivatives; Diagnosis; Prostate cancer; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERIVATIZATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; VALIDATION PROCESS;

EID: 13844296931     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2004.10.009     Document Type: Article

References (26)

1. T.J. Polascik, J.E. Oesterling, and A.W. Partin Prostate specific antigen: A decade of discovery- what we have learned and where we are going J Urol 162 1999 293 306
2. S.H. Landis, T. Murray, and S. Bolden Cancer statistics CA Cancer J Clin 49 1999 8 31
3. W.J. Catalona, P.C. Southwick, K.M. Slawin, A.W. Partin, M.K. Brawer, and R.C. Flanigan Comparison of percent free PSA, PSA density, and age-specific PSA cut-offs for prostate cancer detection and staging Urology 56 2000 255 260
4. T.A. Stamey, and C.E. Yemoto Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: Relationship to transition zone volume J Urol 163 2000 119 126
5. B. Djavan, M. Remzi, and A.R. Zlotta Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: Results of the prospective multicenter European trial Urology 60 4A 2002 4 9
6. S.P. Balk, K. Yoo-Joung, and G.J. Babley Biology of prostate specific antigen J Clin Oncol 21 2 2003 383 391
7. H. Maeda, Y. Arai, and Y. Aohi Complexed prostate-specific antigen and its volume indexes in the detection of prostate cancer Urology 54 1999 225 228
8. T. Saika, T. Tsushima, Y. Nasu, N. Kusaka, Y. Miyaji, and H. Takamoto Prostate specific antigen complexed to α-1-antichymotrypsin in patients with intermediate prostate specific antigen levels Cancer 94 2002 1685 1691
9. C. Fidaner, S.Y. Eser, and D.M. Parkin Incidence in İzmir in 1993-1994: first results from İzmir Cancer Registry European Journal of Cancer 37 2001 83 92
10. H. Ozen, C. Aygun, A. Ergen, S. Sozen, F.T. Aki, and M.C. Uygur Combined use of prostate-specific antigen derivatives decreases the number of unnecessary biopsies to detect prostate cancer Am J Clin Oncol 24 6 2001 610 613
11. K.A. Roehl, J.A.V. Antenor, and W.J. Catalona Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng/ml range J Urol 168 2002 922 925
12. H. Lilja, A. Christensson, U. Dahlen, M.T. Matikainen, O. Nilsson, and K. Pettersson Prostate-specific antigen in serum occurs predominantly in complex with alpha 1- antichymotrypsin Clin Chem 37 1991 1618 1625
13. R.W. Veltri, and M.C. Miller Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: critical analysis of two different test populations Urology 53 1999 736 745
14. M.K. Brawer, G.E. Meyer, J.L. Letran, D.D. Bankson, D.L. Morris, and K.K. Yeung Measurement of complexed PSA improves specificity for early detection of prostate cancer Urology 52 1998 372 378
15. M. Lein, M. Kwiathowski, A. Semjonow, H.J. Luboldt, P. Hammerer, and C. Stephan A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations J Urol 170 2003 1175 1179
16. A.W. Partin, K.B. Brawer, G. Bartch, and W. Horninger Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial J Urol 170 2003 1787 1791
17. K. Jung, U. Elgeti, and M. Lein Ratio of free or complexed prostate specific antigen (PSA) to total PSA: Which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer? Clin Chem 46 2000 55 62
18. Z. Chen, H. Chen, and T.A. Stamey Prostate specific antigen in benign prostatic hyperplasia: purification and characterization J Urol 157 1997 2166 2170
19. Y. Naya, T.A. Stamey, C.D. Cheli, A.W. Partin, L.J. Sokoll, and D.W. Chan Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen? Urology 60 Suppl. 4A 2002 36 41
20. W. Horninger, C.D. Cheli, R.J. Babaian, H.A. Fritche, H. Lepor, and S.S. Taneja Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter Urology 60 2002 31 35
21. J.K. Parsons, M.K. Brawer, C.D. Cheli, A.W. Partin, and R. Djavan Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/ml range of total PSA BJU Int 94 2004 47 50
22. A. Semjonow, B. Brandt, F. Oberpenning, S. Roth, and L. Hertle Discordance of assay methods creates pitfalls for the interpretation of prostate specific antigen values Prostate Suppl 7 1996 3 16
23. H.C. Graves, N. Wehner, and T.A. Stamey Comparison of a polyclonal and monoclonal immunoassay for PSA: need for an international antigen standard J Urology 144 1990 1516 1522
24. C.G. Roehrborn, A. Gregory, J.D. McConnel, A.I. Saglowsky, and F.H. Wians Jr. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate specific antigen in predicting prostate histology Urology 48 1996 23 32
25. A.M. Dnistrian, M.K. Schwartz, C.A. Smith, J.S. Nisselbaum, and W.S. Fair Abbott IMx evaluated for assay of prostate-specific antigen in serum Clin Chem 38 1992 2140 2142
26. R.E. Link, S.F. Shariat, and C.V. Nguyen Variation in prostate specific antigen results from 2 different assay platforms: Clinical impact on 2,304 patients undergoing prostate cancer screening J Urol 171 2004 2234 2238